Lilly's Peglispro superior to Lantus in Type I diabetics

Eli Lilly and Co. (NYSE:LLY) said once-daily basal insulin peglispro ( LY2605541) met the primary endpoint of non-inferiority to Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) in reducing HbA1c from baseline in the Phase III IMAGINE-1 and IMAGINE-3 trials to treat Type I diabetes. IMAGINE-1 trial evaluated the endpoint at week 26, and IMAGINE-3 evaluated the endpoint at week 52. Additionally, Lilly said basal insulin peglispro was superior to Lantus on HbA1c in both trials. All patients also received Lilly's Humalog insulin lispro at mealtimes.

In May, Lilly said basal insulin peglispro met the primary endpoint of non-inferiority to Lantus in the Phase III IMAGINE-2, IMAGINE-4 and IMAGINE-5 trials in Type II diabetics (see BioCentury Extra, May 12). ...